← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

GCTK logoGlucoTrack, Inc.(GCTK)Earnings, Financials & Key Ratios

GCTK•NASDAQ
$0.85
$767646 mkt cap·0.0× P/E·Price updated May 6, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustryPatient monitoring and respiratory care
AboutGlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.Show more
  • Revenue$0
  • EBITDA-$15M-104.6%
  • Net Income-$23M-218.4%
  • EPS (Diluted)60.76+258.6%
  • Interest Coverage-24.95
Technical→

GCTK Key Insights

GlucoTrack, Inc. (GCTK) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

  • ✗Weak Piotroski F-Score: 2/9
  • ✗Weak momentum: RS Rating 2 (bottom 2%)
  • ✗Shares diluted 79.1% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

GCTK Price & Volume

GlucoTrack, Inc. (GCTK) stock price & volume — 10-year historical chart

Loading chart...

GCTK Growth Metrics

GlucoTrack, Inc. (GCTK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-122.14%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-7.17%

Return on Capital

10 Years110.83%
5 Years-183.84%
3 Years-262.18%
Last Year-361.42%

GCTK Peer Comparison

GlucoTrack, Inc. (GCTK) competitors in Patient monitoring and respiratory care — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
DXCM logoDXCMDexCom, Inc.Direct Competitor23.29B60.3628.8815.6%19.31%33.83%0.51
PODD logoPODDInsulet CorporationDirect Competitor10.61B151.1743.4430.73%10.44%21.38%0.69
TNDM logoTNDMTandem Diabetes Care, Inc.Direct Competitor1.24B18.03-5.937.93%-20.17%-141.98%2.86
SENS logoSENSSenseonics Holdings, Inc.Direct Competitor221.18M5.36-3.2356.89%-196.03%-113.21%0.67
NXTC logoNXTCNextCure, Inc.Direct Competitor28.32M10.57-0.54-152.9%0.12
ABT logoABTAbbott LaboratoriesProduct Competitor149.97B86.2511.294.59%31.88%27.26%0.32
LMAT logoLMATLeMaitre Vascular, Inc.Product Competitor2.51B110.2243.7413.53%24.35%16.19%0.47
INVA logoINVAInnoviva, Inc.Product Competitor1.91B22.526.8218.52%118.91%46.47%0.23

Compare GCTK vs Peers

GlucoTrack, Inc. (GCTK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs DXCM

Most directly comparable listed peer for GCTK.

Scale Benchmark

vs LLY

Larger-name benchmark to compare GCTK against a more recognizable public peer.

Peer Set

Compare Top 5

vs DXCM, PODD, TNDM, SENS

GCTK Income Statement

GlucoTrack, Inc. (GCTK) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Sales/Revenue611.69K589.46K43.49K208K000000
Revenue Growth %327.26%-3.63%-92.62%378.29%-100%-----
Cost of Goods Sold59.58K140.21K95.56K047K023K13K36K43K
COGS % of Revenue9.74%23.79%219.75%-------
Gross Profit
552.11K▲ 0%
449.25K▼ 18.6%
-52.08K▼ 111.6%
208K▲ 499.4%
-47K▼ 122.6%
0▲ 100.0%
-23K▲ 0%
-13K▲ 43.5%
-36K▼ 176.9%
-43K▲ 0%
Gross Margin %90.26%76.21%-119.75%100%------
Gross Profit Growth %461.79%-18.63%-111.59%499.42%-122.6%100%-43.48%-176.92%-
Operating Expenses6.27M11.17M6.58M-3.3M3.08M4.04M4.41M7.09M14.51M15.36M
OpEx % of Revenue1024.63%1894.15%15135.41%-1585.58%------
Selling, General & Admin3.31M7.85M3.48M2.06M1.58M2.12M2.46M2.4M5.03M6.57M
SG&A % of Revenue540.6%1331.77%8005.08%992.31%------
Research & Development2.88M3.21M3.03M1.61M1.5M1.81M1.95M4.69M9.48M8.78M
R&D % of Revenue471.12%544.13%6974.02%772.12%------
Other Operating Expenses78.89K107.55K67.98K-6.97M0110K0000
Operating Income
5.66M▲ 0%
10.58M▲ 87.0%
6.54M▼ 38.2%
3.51M▼ 46.4%
-3.13M▼ 189.3%
-4.04M▼ 29.0%
-4.43M▼ 9.7%
-7.1M▼ 60.3%
-14.55M▼ 104.8%
-15.4M▲ 0%
Operating Margin %924.63%1794.15%15035.41%1685.58%------
Operating Income Growth %21.49%86.99%-38.17%-46.38%-189.33%-28.99%-9.7%-60.29%-104.77%-
EBITDA5.72M10.64M6.6M3.56M-3.08M-4M-4.41M-7.09M-14.51M-15.36M
EBITDA Margin %934.37%1805.67%15170.6%1710.1%------
EBITDA Growth %21.6%86.23%-38.02%-46.08%-186.73%-29.59%-10.28%-60.83%-104.64%28.37%
D&A (Non-Cash Add-back)59.58K67.88K58.79K51K47K42K23K13K36K43K
EBIT-5.39M-10.3M-6.7M-3.51M-2.7M-3.98M-4.43M-7.1M-22.01M-24.92M
Net Interest Income-15.59K-27.43K-17.36K-10K98K26K8K7K-583K-543K
Interest Income62900-98K26K11K7K01.3M
Interest Expense16.22K24.4K18.29K10K003K0583K1.85M
Other Income/Expense246.1K247.04K-176.82K-7.02M436K-27K-3K7K-8.05M-11.37M
Pretax Income
-5.41M▲ 0%
-10.33M▼ 90.9%
-6.72M▲ 35.0%
-3.52M▲ 47.6%
-2.7M▲ 23.3%
-4.07M▼ 50.9%
-4.43M▼ 9.0%
-7.1M▼ 60.0%
-22.6M▼ 218.4%
-26.77M▲ 0%
Pretax Margin %-884.39%-1752.24%-15442.01%-1690.38%------
Income Tax16.22K24.4K-13.24M0000000
Effective Tax Rate %-0.3%-0.24%197.09%0%0%0%0%0%0%0%
Net Income
-5.41M▲ 0%
-10.33M▼ 90.9%
-6.72M▲ 35.0%
-3.52M▲ 47.6%
-2.7M▲ 23.3%
-4.07M▼ 50.9%
-4.43M▼ 9.0%
-7.1M▼ 60.0%
-22.6M▼ 218.4%
-26.77M▲ 0%
Net Margin %-884.39%-1752.24%-15442.01%-1690.38%------
Net Income Growth %7.4%-90.93%34.98%47.64%23.32%-50.85%-9.05%-60.02%-218.4%-122.14%
Net Income (Continuing)-5.41M-10.33M-6.72M-3.52M-2.7M-4.07M-4.43M-7.1M-22.6M-26.77M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)
0.00▲ 0%
0.00▲ 0%
0.00▲ 0%
-29.50▲ 0%
-17.88▲ 39.4%
-26.32▼ 47.2%
-28.66▼ 8.9%
-38.30▼ 33.6%
60.76▲ 258.6%
-54.14▲ 0%
EPS Growth %----39.39%-47.2%-8.89%-33.64%258.64%-7.17%
EPS (Basic)0.000.000.00-29.50-17.88-26.32-28.66-38.3060.76-
Diluted Shares Outstanding000119.18K150.79K154.51K154.75K207.6K371.91K494.5K
Basic Shares Outstanding000119K150K154K154K185K371.91K494.5K
Dividend Payout Ratio----------

GCTK Balance Sheet

GlucoTrack, Inc. (GCTK) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Total Current Assets2.02M1.23M314.14K718K10.23M6.11M2.38M4.87M5.77M10.08M
Cash & Short-Term Investments148.84K53.78K97.08K419K9.82M6.06M2.31M4.49M5.62M9.55M
Cash Only148.84K53.78K97.08K419K9.82M6.06M2.31M4.49M5.62M9.55M
Short-Term Investments0000000000
Accounts Receivable92.06K121.78K22.78K70K66K00000
Days Sales Outstanding54.9375.41191.19122.84------
Inventory1.42M957.35K171K184K284K00000
Days Inventory Outstanding8.7K2.49K653.13-2.21K-----
Other Current Assets266.43K63.82K9.7K21.71K56K43K67K376K151K522K
Total Non-Current Assets443.45K441.88K374.04K378K377K160K59K37K164K133K
Property, Plant & Equipment240.45K216.75K149.78K321K315K109K40K27K154K133K
Fixed Asset Turnover2.54x2.72x0.29x0.65x-----0.00x
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments35.67K39.56K52.6K0051K15K010K30K
Other Non-Current Assets167.33K185.57K171.66K57K62K04K10K00
Total Assets
2.46M▲ 0%
1.67M▼ 32.2%
688.19K▼ 58.8%
1.1M▲ 59.3%
10.61M▲ 867.7%
6.26M▼ 40.9%
2.44M▼ 61.1%
4.91M▲ 101.2%
5.93M▲ 20.9%
10.21M▲ 0%
Asset Turnover0.25x0.35x0.06x0.19x-----0.00x
Asset Growth %15.39%-32.18%-58.76%59.26%867.7%-40.93%-61.09%101.19%20.94%1868.1%
Total Current Liabilities2.35M3.69M3.22M2.27M1.34M883K1.01M1.51M1.27M3.08M
Accounts Payable1.63M2.42M2.06M1.53M869K631K672K839K992K2.64M
Days Payables Outstanding10.01K6.3K7.88K-6.75K-10.66K23.56K10.06K15.08K
Short-Term Debt000000005K0
Deferred Revenue (Current)0000000000
Other Current Liabilities363.74K336.78K239.96K195K244K0341K673K252K414K
Current Ratio0.86x0.33x0.10x0.32x7.61x6.91x2.35x3.22x4.52x4.52x
Quick Ratio0.25x0.07x0.04x0.24x7.39x6.91x2.35x3.22x4.52x4.52x
Cash Conversion Cycle-1.26K-3.73K-7.04K-------
Total Non-Current Liabilities11.06M14.56M339.88K236K279K227K195K196K17.66M245K
Long-Term Debt162.03K182.77K168.22K191K197K210K195K196K203K221K
Capital Lease Obligations00045K82K17K0033K118K
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities10.9M14.38M171.66K0000017.42M17.6M
Total Liabilities13.41M18.24M3.56M2.51M1.62M1.11M1.21M1.71M18.93M3.33M
Total Debt162.03K182.77K168.22K378K363K250K195K196K267K267K
Net Debt13.2K128.99K71.14K-41K-9.46M-5.81M-2.12M-4.3M-5.35M-9.29M
Debt / Equity----0.04x0.05x0.16x0.06x-0.04x
Debt / EBITDA0.03x0.02x0.03x0.11x------0.02x
Net Debt / EBITDA0.00x0.01x0.01x-0.01x-----0.60x
Interest Coverage348.78x433.51x357.50x350.60x---1477.33x--24.95x-13.49x
Total Equity
-10.95M▲ 0%
-16.57M▼ 51.4%
-2.87M▲ 82.7%
-1.41M▲ 50.9%
8.98M▲ 736.1%
5.16M▼ 42.6%
1.23M▼ 76.1%
3.2M▲ 159.9%
-13M▼ 506.6%
6.88M▲ 0%
Equity Growth %-57.07%-51.38%82.66%50.86%736.12%-42.61%-76.14%159.92%-506.63%1460.49%
Book Value per Share-1.82-2.43--11.8559.5733.367.9515.40-34.9513.91
Total Shareholders' Equity-10.95M-16.57M-2.87M-1.41M8.98M5.16M1.23M3.2M-13M6.88M
Common Stock6.03K6.82K141.64K162K15K15K15K20K1K1K
Retained Earnings-35.6M-47.37M-87.19M-90.7M-93.4M-97.47M-101.9M-109.85M-132.45M-144.04M
Treasury Stock0000000000
Accumulated OCI62.58K110.67K164.23K124K15K-6K17K64K-8K41K
Minority Interest0000000000

GCTK Cash Flow Statement

GlucoTrack, Inc. (GCTK) cash flow — operating, investing & free cash flow history

Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Cash from Operations-5.31M-5.9M-4.89M-3.9M-3.5M-3.77M-3.73M-6.56M-12.49M-12.49M
Operating CF Margin %-868.39%-1000.08%-11249.72%-1874.56%------
Operating CF Growth %-16.35%-10.98%17.01%20.3%10.21%-7.66%1.06%-75.86%-90.45%-261.67%
Net Income-5.41M-10.33M-6.72M-3.52M-2.7M-4.07M-4.43M-7.1M-22.6M-26.77M
Depreciation & Amortization59.58K67.88K58.79K50.59K47K42K23K13K36K43K
Stock-Based Compensation70.25K2.71M705.25K512.38K22K223K439K281K173K25K
Deferred Taxes-78.55K-300.32K00042K0000
Other Non-Cash Items-6293.03K-9277.55K160K44K60K55K9.83M13.08M
Working Capital Changes47.25K1.96M1.06M-953.47K-1.03M-53K184K190K67K-699K
Change in Receivables-73.44K-19.27K89.31K-44.04K10K68K0000
Change in Inventory-590.62K608.21K720.38K953-85K293K0000
Change in Payables526.56K620.8K-261.92K-600.35K-714K-257K74K167K263K18K
Cash from Investing-76.45K-19.47K-5.37K-23.43K-53K-1K1K0-104K-42K
Capital Expenditures-76.45K-19.47K-5.37K-23.43K-53K-5K-1K0-104K-42K
CapEx % of Revenue12.5%3.3%12.35%11.27%------
Acquisitions0000002K000
Investments----------
Other Investing000004K2000
Cash from Financing4.94M5.75M4.96M4.2M13.01M008.73M13.74M23.72M
Debt Issued (Net)000000004.38M4.36M
Equity Issued (Net)1000K1000K1000K1000K1000K001000K1000K3M
Dividends Paid-13.53K-5.73K00000000
Share Repurchases0000000000
Other Financing1.64M1.95M2.26M33K000085K-143K
Net Change in Cash
-459.87K▲ 0%
-95.05K▲ 79.3%
56.34K▲ 159.3%
326.03K▲ 478.7%
9.41M▲ 2785.9%
-3.77M▼ 140.1%
-3.78M▼ 0.3%
2.17M▲ 157.4%
1.13M▼ 48.2%
9.39M▲ 0%
Free Cash Flow
-5.39M▲ 0%
-5.91M▼ 9.8%
-4.9M▲ 17.2%
-3.92M▲ 19.9%
-3.55M▲ 9.4%
-3.77M▼ 6.2%
-3.73M▲ 1.2%
-6.56M▼ 75.8%
-12.59M▼ 92.0%
-14.37M▲ 0%
FCF Margin %-880.89%-1003.39%-11262.07%-1885.83%------
FCF Growth %-14.43%-9.77%17.19%19.91%9.4%-6.19%1.17%-75.82%-92.04%-55.97%
FCF per Share-0.89-0.87--32.91-23.57-24.43-24.10-31.59-33.86-33.86
FCF Conversion (FCF/Net Income)0.98x0.57x0.73x1.11x1.30x0.93x0.84x0.92x0.55x0.54x
Interest Paid00000000077K
Taxes Paid0000000000

GCTK Key Ratios

GlucoTrack, Inc. (GCTK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201620172018201920202021202220232024TTM
Return on Equity (ROE)-----71.23%-57.54%-138.92%-320.62%--389.1%
Return on Invested Capital (ROIC)---------188.94%
Gross Margin90.26%76.21%-119.75%100%------
Net Margin-884.39%-1752.24%-15442.01%-1690.38%------
Debt / Equity----0.04x0.05x0.16x0.06x-0.04x
Interest Coverage348.78x433.51x357.50x350.60x---1477.33x--24.95x-13.49x
FCF Conversion0.98x0.57x0.73x1.11x1.30x0.93x0.84x0.92x0.55x0.54x
Revenue Growth327.26%-3.63%-92.62%378.29%-100%-----

GCTK Frequently Asked Questions

GlucoTrack, Inc. (GCTK) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

GlucoTrack, Inc. (GCTK) grew revenue by 0.0% over the past year. Growth has been modest.

GlucoTrack, Inc. (GCTK) reported a net loss of $26.8M for fiscal year 2024.

Dividend & Returns

GlucoTrack, Inc. (GCTK) had negative free cash flow of $14.4M in fiscal year 2024, likely due to heavy capital investments.

Explore More GCTK

GlucoTrack, Inc. (GCTK) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.